TABLE 3.

Effects of central drug infusion on sexual behavior (after central drug infusion)

	Con‐IF	nED‐vehicle	nED‐D1+	nED‐D1‐	nED‐D2+	nED‐D2‐
ML (s)	40.3 ± 2.1	239.9 ± 68.4	226.5 ± 84.3	249.3 ± 72.2	52.9 ± 8.7*	378.9 ± 60.8
IL (s)	42.5 ± 2.0	303.4 ± 78.8	312.6 ± 86.8	319.4 ± 76.3	67.8 ± 10.3	478.1 ± 56.7
MF	16.4 ± 1.6	13.9 ± 1.3	12.1 ± 1.4	11.1 ± 0.8	14.8 ± 1.6	8.1 ± 0.3**
IF	25.4 ± 3.0	9.5 ± 1.0	9.4 ± 1.6	7.7 ± 1.1	21.3 ± 1.5	3.0 ± 0.3*
IR	0.610 ± 0.014	0.403 ± 0.016	0.426 ± 0.018	0.393 ± 0.024	0.595 ± 0.018*	0.266 ± 0.012

Note: The data are presented as the mean ± standard error of mean (SEM).

Abbreviations: Con‐IF, control group for immunofluorescence analysis; IF, intromission frequency; IL, intromission latency; IR, intromission ratio; nED, nonorganic erectile dysfunction; MF, mount frequency; ML, mount latency.

^* p < 0.05.

^** p < 0.005 different from nED‐vehicle group (control group was not included in the comparison).